Daily Orforglipron Treatment Reduces Weight and Blood Sugar in Seniors

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

New post-hoc analysis examined daily oral orforglipron in adults over 65 with obesity, with or without diabetes

A new analysis presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial program population.

New Post-Hoc Analysis Explores Daily Oral Orforglipron Use in Adults Over

A groundbreaking new analysis set to be unveiled at the European Congress on Obesity (ECO 2026) in Istanbul delves into the efficacy and safety of orforglipron, an innovative oral glucagon-like peptide-1 receptor agonist (GLP-1 RA), in treating obesity among older adults aged 65 and above, both with and without type 2 diabetes mellitus (T2D). This investigation, led by Dr. Deborah Horn of the McGovern Medical School’s Center for Obesity Medicine…